Literature DB >> 30737678

Influence of proton pump inhibitors on microbiota in chronic liver disease patients.

Kenta Yamamoto1, Masatoshi Ishigami2, Takashi Honda1, Tomoaki Takeyama1, Takanori Ito1, Yoji Ishizu1, Teiji Kuzuya1, Kazuhiko Hayashi1, Hidemi Goto1, Yoshiki Hirooka1.   

Abstract

BACKGROUND: Current knowledge suggests that proton pump inhibitors (PPIs) are associated with an increased risk of hepatic encephalopathy (HE) and spontaneous bacterial peritonitis (SBP). These conditions and PPI use are related to gut microbiota. The aim of this study is to research the changes in gut microbiota caused by PPI in patients with chronic liver disease.
METHODS: From 198 Japanese patients, 31 patients in the PPI and non-PPI groups were matched using propensity score matching (PSM) based on age, sex, and Child-Turcotte-Pugh class. We investigated the gut microbial composition of stool samples using the Illumina MiSeq sequencing platform and compared them using linear discriminant analysis effect size and phylogenetic investigation of communities by reconstruction of unobserved states.
RESULTS: Before PSM, Child-Turcotte-Pugh score (p = 0.038), ascites (p = 0.049), encephalopathy (p = 0.023), and esophageal varices (p < 0.01) were significantly higher in the PPI group than in the non-PPI group. After PSM, six genera, consisting of Lactobacillus, Streptococcus, Selenomonas, Veillonella, Campylobacter, and Haemophilus were enriched in the PPI group. Eggerthella, Paraprevotella, Turicibacter, Dorea, Anaerotruncus, and Ruminococcus were less abundant in the PPI group. We identified five types of level 3 KEGG pathways predicted to be significantly different.
CONCLUSIONS: Part of microbial changes caused by PPI use was common to the changes by progression of liver cirrhosis. Increases in oral bacterial flora and decreases in autochthonous flora may produce the intestinal environment which tends to make the risk factor for HE or SBP.

Entities:  

Keywords:  Liver; Microbiota; Next generation sequencing; Propensity score matching methods; Proton pump inhibitor

Mesh:

Substances:

Year:  2019        PMID: 30737678     DOI: 10.1007/s12072-019-09932-9

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  32 in total

Review 1.  Cultivable bacterial diversity from the human colon.

Authors:  S H Duncan; P Louis; H J Flint
Journal:  Lett Appl Microbiol       Date:  2007-04       Impact factor: 2.858

2.  Propensity scores: from naive enthusiasm to intuitive understanding.

Authors:  Elizabeth Williamson; Ruth Morley; Alan Lucas; James Carpenter
Journal:  Stat Methods Med Res       Date:  2011-01-24       Impact factor: 3.021

3.  Linkage of gut microbiome with cognition in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Jason M Ridlon; Phillip B Hylemon; Leroy R Thacker; Douglas M Heuman; Sean Smith; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-22       Impact factor: 4.052

Review 4.  The role of microbiota in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Gut Microbes       Date:  2014-04-01

5.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

6.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Authors:  Genta Kakiyama; William M Pandak; Patrick M Gillevet; Phillip B Hylemon; Douglas M Heuman; Kalyani Daita; Hajime Takei; Akina Muto; Hiroshi Nittono; Jason M Ridlon; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Leroy R Thacker; Masoumeh Sikaroodi; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-01-16       Impact factor: 25.083

7.  Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.

Authors:  Zhigang Zhang; Huiqin Zhai; Jiawei Geng; Rui Yu; Haiqing Ren; Hong Fan; Peng Shi
Journal:  Am J Gastroenterol       Date:  2013-07-23       Impact factor: 10.864

8.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

9.  Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  J Hepatol       Date:  2013-12-25       Impact factor: 25.083

Review 10.  Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.

Authors:  Abhishek Deshpande; Vinay Pasupuleti; Priyaleela Thota; Chaitanya Pant; Sulaiman Mapara; Sohaib Hassan; David D K Rolston; Thomas J Sferra; Adrian V Hernandez
Journal:  J Gastroenterol Hepatol       Date:  2013-02       Impact factor: 4.029

View more
  9 in total

1.  The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan.

Authors:  Akira Sakamaki; Kenya Kamimura; Takeshi Yokoo; Akihiko Osaki; Seiichi Yoshikawa; Yoshihisa Arao; Toru Setsu; Hiroteru Kamimura; Nobuo Waguri; Manabu Takeuchi; Kazuhiro Funakoshi; Shuji Terai
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 2.  Association Between Proton Pump Inhibitor Therapy and Spontaneous Bacterial Peritonitis Occurrence in Cirrhotic Patients: A Clinical Review.

Authors:  Meng Zhang; Wei Liu; Xin Xu; Tao Chen; Jun-Ying Qi
Journal:  Curr Med Sci       Date:  2022-07-23

3.  Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan.

Authors:  Motonobu Hamazaki; Tsunaki Sawada; Takeshi Yamamura; Keiko Maeda; Yasuyuki Mizutani; Eri Ishikawa; Satoshi Furune; Kenta Yamamoto; Takuya Ishikawa; Naomi Kakushima; Kazuhiro Furukawa; Eizaburo Ohno; Takashi Honda; Hiroki Kawashima; Masatoshi Ishigami; Masanao Nakamura; Mitsuhiro Fujishiro
Journal:  BMC Gastroenterol       Date:  2022-07-14       Impact factor: 2.847

4.  Preliminary Comparison of Endoscopic Brush and Net Catheters as the Sampling Tool to Analyze the Intestinal Mucus in the Rectum with Ulcerative Colitis Patients.

Authors:  Masanao Nakamura; Keiko Maeda; Kenta Yamamoto; Takeshi Yamamura; Tsunaki Sawada; Eri Ishikawa; Naomi Kakushima; Kazuhiro Furukawa; Tadashi Iida; Yasuyuki Mizutani; Takuya Ishikawa; Eizaburo Ohno; Takashi Honda; Masatoshi Ishigami; Hiroki Kawashima
Journal:  Digestion       Date:  2022-02-18       Impact factor: 3.672

5.  Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Meng Zhang; Xin Xu; Wei Liu; Zhongwei Zhang; Qiuyu Cheng; Zhongyuan Yang; Tingting Liu; Yunhui Liu; Qin Ning; Tao Chen; Junying Qi
Journal:  Adv Ther       Date:  2021-07-25       Impact factor: 3.845

6.  Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis.

Authors:  Hisanori Muto; Takanori Ito; Taku Tanaka; Shinya Yokoyama; Kenta Yamamoto; Norihiro Imai; Yoji Ishizu; Keiko Maeda; Takashi Honda; Tetsuya Ishikawa; Asuka Kato; Taichi Ohshiro; Fumiya Kano; Akihito Yamamoto; Kiyoshi Sakai; Hideharu Hibi; Masatoshi Ishigami; Mitsuhiro Fujishiro
Journal:  Sci Rep       Date:  2021-09-21       Impact factor: 4.379

7.  Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy.

Authors:  Yong Lin; Gengjie Yan; Feng Feng; Minggang Wang; Fuli Long
Journal:  Open Life Sci       Date:  2022-03-10       Impact factor: 0.938

8.  Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease.

Authors:  Kenta Yamamoto; Yoji Ishizu; Takashi Honda; Takanori Ito; Norihiro Imai; Masanao Nakamura; Hiroki Kawashima; Yasuyuki Kitaura; Masatoshi Ishigami; Mitsuhiro Fujishiro
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

9.  Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.

Authors:  Ansgar W Lohse; Johannes Kluwe; Malte H Wehmeyer; Thomas Horvatits; Anika Buchholz; Linda Krause; Sarah Walter; Antonia Zapf
Journal:  Trials       Date:  2022-04-12       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.